Neetu Chandra Sharma is a senior editor at Business Today Magazine. Currently leading the health and pharma coverage, she extensively writes on topics such as public health, the pharmaceutical industry, health financing, and the corporate sector, with a focus on healthcare systems and technologies. Neetu's work has been featured in MSN and Business Today.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Neetu Chandra Sharma's coverage primarily focuses on the healthcare and pharmaceutical industry in India. She frequently includes data, press releases, government announcements, and private sector developments in her articles. To effectively reach out to Neetu Chandra Sharma, consider offering access to exclusive data or insights related to the Indian healthcare sector. Additionally, pitches that provide analysis of government policies or initiatives impacting healthcare or pharmaceuticals in India are likely to resonate with her coverage focus.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Neetu Chandra Sharma In a Jan Aushadhi store in Patna, Bihar, a strip of paracetamol costs Rs 3.
By: Neetu Chandra Sharma
Partnership with Guardant Health expands access to multi-cancer screening as precision diagnostics emerges as a new growth area
By: Neetu Chandra Sharma
Over 38,000 new beds are expected by 2030 as hospital chains bet on speciality care, medical tourism and rising insurance coverage
By: Neetu Chandra Sharma
Hospital chain signs O&M agreement with Dion Group for greenfield multi-speciality facility in Cuttack as it expands beyond its existing markets.
By: Neetu Chandra Sharma
Neetu Chandra Sharma Zydus Lifesciences has partnered with Apollo Hospitals to introduce Guardant Health's Shield multi-cancer detection (MCD) blood
By: Neetu Chandra Sharma
Neetu Chandra Sharma Fortis Healthcare is expanding into Odisha through an asset-light model, signing an operations and management (O&M) agreement
After spending nearly Rs 6,800 crore and more than two decades, Wockhardt has achieved what no Indian pharmaceutical company has before: US FDA approval for a novel drug discovered and developed in-house. Zaynich is expected to drive Wockhardt's next phase of growth after it returned to profitability in FY26.
By: Neetu Chandra Sharma
India becomes seventh market for Awiqli as drugmaker targets delays in insulin initiation among people with diabetes.
By: Neetu Chandra Sharma
PB Fintech has opened its first hospital in Gurugram as it seeks to bring medical care, insurance and technology together under the PB Health brand.
By: Neetu Chandra Sharma
New global guidance also recommends tackling obesity, diabetes and hearing loss; AIIMS and NIMHANS experts contributed to the report
